rc48-adc
Cervical Carcinoma
SOLTI Breast Cancer Research Groupantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
47 Active assets in the Cervical Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide City of Hope Medical Center | Phase 2 | BB |
Epirubicin Mayo Clinic | Phase 2 | BB |
Hycamtin Advenchen Laboratories, LLC | Phase 3 | BB |
Pembrolizumab Mayo Clinic | Phase 2 | BB |
Nivolumab Fred Hutchinson Cancer Center | Phase 2 | B |
View all 50 →
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →